The Risk of QTc Prolongation with Antiemetics in the Palliative Care Setting: A Narrative Review

References

• Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348–353. doi:10.1007/s00520-005-0897-1.
   PubMed Web of Science ®Google Scholar
• Wood GJ, Shega JW, Lynch B, Von Roenn JH. Management of intractable nausea and vomiting in patients at the end of life: “I was feeling nauseous all of the time . . . nothing was working”. JAMA. 2007;298(10):1196–1207. doi:10.1001/jama.298.10.1196.
   PubMed Web of Science ®Google Scholar
• Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E, Jerzak KJ. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019;27(1):87–95. doi:10.1007/s00520-018-4464-y.
   PubMed Web of Science ®Google Scholar
• Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. Heart. 2017;42(7):473–477.
   Google Scholar
• van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol. 2010;70(1):16–23. doi:10.1111/j.1365-2125.2010.03660.x.
   PubMed Web of Science ®Google Scholar
• Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clin Interv Aging. 2011;6:243–259. doi:10.2147/CIA.S13109.
   PubMed Web of Science ®Google Scholar
• Flake ZA, Scalley RD, Bailey AG. Practical selection of antiemetics. Am Fam Physician. 2004;69(5):1169–1174.
   PubMed Web of Science ®Google Scholar
• Yates BJ, Catanzaro MF, Miller DJ, McCall AA. Integration of vestibular and emetic gastrointestinal signals that produce nausea and vomiting: potential contributions to motion sickness. Exp Brain Res. 2014;232(8):2455–2469. doi:10.1007/s00221-014-3937-6.
   PubMed Web of Science ®Google Scholar
• Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor-the relationship between structure and function. Neuropharmacology. 2009;56(1):273–284. doi:10.1016/j.neuropharm.2008.08.003.
   PubMed Web of Science ®Google Scholar
• Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179–185. doi:10.2147/CMAR.S34352.
   PubMedGoogle Scholar
• Tricco AC, Blondal E, Veroniki AA, Soobiah C, Vafaei A, Ivory J, Strifler L, Cardoso R, Reynen E, Nincic V, et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med. 2016;14(1):216. doi:10.1186/s12916-016-0761-9.
   PubMed Web of Science ®Google Scholar
• Zuo P, Haberer LJ, Fang L, Hunt TL, Ridgway D, Russo MW. Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study. J Clin Pharmacol. 2014;54(11):1221–1229. doi:10.1002/jcph.322.
   PubMed Web of Science ®Google Scholar
• FDA Drug safety communication: updated information on 32mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products. Food and Drug Administration Web Site. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-information-32-mg-intravenous-ondansetron-zofran-dose-and-pre. Published March, 7 2016. Accessed August 31, 2020.
   Google Scholar
• Gupta SD, Pal R, Sarkar A, Mukherjee S, Mitra K, Roy S, Sarbapalli D, Kundu KK, Zaman FA, Kar S. Evaluation of Ondansetron-induced QT interval prolongation in the prophylaxis of postoperative emesis. J Nat Sci Biol Med. 2011;2(1):119–124. doi:10.4103/0976-9668.82306.
   PubMedGoogle Scholar
• FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Food and Drug Administration Web Site. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-associated-use-anzemet-dolasetron-mesylate. Published online August 3, 2017. Accessed August 31, 2020.
   Google Scholar
• Benedict CR, Arbogast R, Martin L, Patton L, Morrill B, Hahne W. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28(1):53–59. doi:10.1097/00005344-199607000-00009.
   PubMed Web of Science ®Google Scholar
• Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res. 2012;18(10):2913–2921. doi:10.1158/1078-0432.CCR-11-2785.
   PubMed Web of Science ®Google Scholar
• Mason JW, Moon TE, O'Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res. 2014;6:181–190. doi:10.2147/CMAR.S58071.
   PubMed Web of Science ®Google Scholar
• Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer. 2016;24(2):621–627. doi:10.1007/s00520-015-2822-6.
   PubMed Web of Science ®Google Scholar
• Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterol Motil. 2019;31(11):e13617. doi:10.1111/nmo.13617.
   PubMedGoogle Scholar
• Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119–v133. doi:10.1093/annonc/mdw270.
   PubMed Web of Science ®Google Scholar
• Fujiki A, Sakabe M. Differences in the slope of the QT-RR relation based on 24-hour holter ECG recordings between cardioembolic and atherosclerotic stroke. Intern Med. 2016;55(20):2927–2932. doi:10.2169/internalmedicine.55.6702.
   PubMed Web of Science ®Google Scholar
• Ellidokuz E, Kaya D. The effect of metoclopramide on QT dynamicity: double-blind, placebo-controlled, cross-over study in healthy male volunteers. Aliment Pharmacol Ther. 2003;18(1):151–155. doi:10.1046/j.1365-2036.2003.01641.x.
   PubMed Web of Science ®Google Scholar
• Siddique SM, Shariff N, Vesuwala N, Hafiz T. Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med. 2009;150(7):502–504. doi:10.7326/0003-4819-150-7-200904070-00016.
   PubMed Web of Science ®Google Scholar
• Chou CC, Wu D. Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J. 2001;24(12):805–809.
   PubMedGoogle Scholar
• McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–135. doi:10.3109/15360288.2013.782937.
   PubMedGoogle Scholar
• Kamali A, Ahmadi L, Shokrpour M, Pazuki S. Investigation of ondansetron, haloperidol, and dexmedetomidine efficacy for prevention of postoperative nausea and vomiting in patients with abdominal hysterectomy. Open Access Maced J Med Sci. 2018;6(9):1659–1663. doi:10.3889/oamjms.2018.366.
   PubMedGoogle Scholar
• Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. J Pain Symptom Manage. 2010;40(1):111–116. doi:10.1016/j.jpainsymman.2009.11.321.
   PubMed Web of Science ®Google Scholar
• Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des. 2006;12(18):2271–2283. doi:10.2174/138161206777585102.
   PubMed Web of Science ®Google Scholar
• Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. 2013 Jan-Feb;54(1):1–13. doi:10.1016/j.psym.2012.11.001.
   PubMed Web of Science ®Google Scholar
• Duprey MS, Al-Qadheeb N, Roberts R, Skrobik Y, Schumaker G, Devlin JW. The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial. Intensive Care Med. 2016;42(11):1818–1819. doi:10.1007/s00134-016-4512-3.
   PubMed Web of Science ®Google Scholar
• Page VJ, Ely EW, Gates S, Zhao XB, Alce T, Shintani A, Jackson J, Perkins GD, McAuley DF. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2013;1(7):515–523. doi:10.1016/S2213-2600(13)70166-8.
   PubMed Web of Science ®Google Scholar
• Desai M, Li L, Desta Z, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol. 2003;55(6):511–517. doi:10.1046/j.1365-2125.2003.01791.x.
   PubMed Web of Science ®Google Scholar
• Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018;9(9):CD012555. doi:10.1002/14651858.CD012555.pub2.
   PubMedGoogle Scholar
• Ettinger DS, Berger MJ, Barbour S, et al. Antiemesis. NCCN guidelines; 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
   Google Scholar
• Olanzapine (package insert). Acetris Health, LLC, Saddle Brook, NJ; September 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=13591d0b-0d4a-4bb4-bf49-d54ba5ca1759. Accessed August 31, 2020.
   Google Scholar
• Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014;5(1):24–29. doi:10.6004/jadpro.2014.5.1.8.
   PubMedGoogle Scholar
• Qadri SF, Padala PR, Strunk JC, Boust SJ. High-dose olanzapine orally disintegrating tablets for treatment-resistant psychosis. Prim Care Companion J Clin Psychiatry. 2006;8(4):244–245. doi:10.4088/pcc.v08n0410a.
   PubMedGoogle Scholar
• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341–356. doi:10.1002/wps.20567.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ono S, Sugai T, Fukui N, Watanabe J, Tsuneyama N, Sawamura K, Someya T. Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Hum Psychopharmacol. 2011;26(6):440–443. doi:10.1002/hup.1218.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sugai T, Ono S, Sawamura K, Fukui N, Watanabe J, Tsuneyama N, Saito M, Someya T. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry Clin Neurosci. 2014;68(5):353–356. doi:10.1111/pcn.12136.
   PubMed Web of Science ®Google Scholar
• Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–69. doi:10.1097/01.jcp.0000104913.75206.62.
   PubMed Web of Science ®Google Scholar
• Gurovich I, Vempaty A, Lippmann S. QTc prolongation: chlorpromazine and high-dosage olanzapine. Can J Psychiatry. 2003;48(5):348. doi:10.1177/070674370304800513.
   PubMed Web of Science ®Google Scholar
• Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):401–405. doi:10.1016/j.pnpbp.2010.01.008.
   PubMed Web of Science ®Google Scholar
• Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5(5):205–215. doi:10.4088/pcc.v05n0504.
   PubMedGoogle Scholar
• Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64(11):1174–1186. doi:10.2146/ajhp060505.
   PubMed Web of Science ®Google Scholar
• Athavale A, Athavale T, Roberts DM. Antiemetic drugs: what to prescribe and when. Aust Prescr. 2020;43(2):49–56. doi:10.18773/austprescr.2020.011.
   PubMed Web of Science ®Google Scholar
• Cole JB, Lee SC, Martel ML, Smith SW, Biros MH, Miner JR. The incidence of QT prolongation and torsades des pointes in patients receiving droperidol in an urban emergency department. West J Emerg Med. 2020;21(4):728–736. doi:10.5811/westjem.2020.4.47036.
   PubMed Web of Science ®Google Scholar
• Calver L, Isbister GK. High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings. Br J Clin Pharmacol. 2014 May;77(5):880–886. doi:10.1111/bcp.12272.
   PubMed Web of Science ®Google Scholar
• Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg. 1994;79(5):983–986. doi:10.1213/00000539-199411000-00028.
   PubMed Web of Science ®Google Scholar
• Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology. 2005;102(6):1094–1100. doi:10.1097/00000542-200506000-00006.
   PubMed Web of Science ®Google Scholar
• Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med. 2012;1(2):137–142. doi:10.3978/j.issn.2224-5820.2012.07.09.
   PubMedGoogle Scholar
• Correll CU, Harris J, Figen V, Kane JM, Manu P. Antipsychotic drug administration does not correlate with prolonged rate-corrected QT interval in children and adolescents: results from a nested case-control study. J Child Adolesc Psychopharmacol. 2011;21(4):365–368. doi:10.1089/cap.2011.0024.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson S, Clinch T. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171–1176. doi:10.1016/j.parkreldis.2014.08.010.
   PubMed Web of Science ®Google Scholar
• Lee BH, Lee SH, Chu D, Hyun JW, Choe H, Choi BH, Jo SH. Effects of the histamine H(1) receptor antagonist hydroxyzine on hERG K(+) channels and cardiac action potential duration. Acta Pharmacol Sin. 2011;32(9):1128–1137. doi:10.1038/aps.2011.66.
   PubMed Web of Science ®Google Scholar
• Owczuk R, Twardowski P, Dylczyk-Sommer A, Wujtewicz MA, Sawicka W, Drogoszewska B, Wujtewicz M. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study. Anaesthesia. 2009;64(6):609–614. doi:10.1111/j.1365-2044.2009.05890.x.
   PubMed Web of Science ®Google Scholar
• Nolen A, Dai T. Diphenhydramine use disorder and complicated withdrawal in a palliative care patient. J Palliat Med. 2020;23(9):1279–1282. doi:10.1089/jpm.2019.0308.
   PubMed Web of Science ®Google Scholar
• Shah A, Yousuf T, Ziffra J, Zaidi A, Raghuvir R. Diphenhydramine and QT prolongation - a rare cardiac side effect of a drug used in common practice. J Cardiol Cases. 2015;12(4):126–129. doi:10.1016/j.jccase.2015.06.002.
   PubMedGoogle Scholar
• Thakur AC, Aslam AK, Aslam AF, Vasavada BC, Sacchi TJ, Khan IA. QT interval prolongation in diphenhydramine toxicity. Int J Cardiol. 2005;98(2):341–343. doi:10.1016/j.ijcard.2003.10.051.
   PubMed Web of Science ®Google Scholar
• Schlit AF, Delaunois A, Colomar A, Claudio B, Cariolato L, Boev R, Valentin JP, Peters C, Sloan VS, Bentz JWG. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect. 2017;5(3):e00309. doi:10.1002/prp2.309.
   PubMed Web of Science ®Google Scholar
• Spiller JA, Fallon M. The use of Scopoderm in palliative care. Hosp Med. 2000;61(11):782–784. doi:10.12968/hosp.2000.61.11.1464.
   PubMedGoogle Scholar
• Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011;163(7):1411–1422. doi:10.1111/j.1476-5381.2010.01176.x.
   PubMed Web of Science ®Google Scholar
• Yun J, Yoon KS, Lee TH, Lee H, Gu SM, Song YJ, Cha HJ, Han KM, Seo H, Shin J, et al. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res (Camb)). 2016;5(6):1663–1671. doi:10.1039/c6tx00259e.
   PubMed Web of Science ®Google Scholar
• Machado Rocha FC, Stéfano SC, De Cássia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl)). 2008;17(5):431–443. doi:10.1111/j.1365-2354.2008.00917.x.
   PubMed Web of Science ®Google Scholar
• Desai R, Patel U, Deshmukh A, Sachdeva R, Kumar G. Burden of arrhythmia in recreational marijuana users. Int J Cardiol. 2018;264:91–92. doi:10.1016/j.ijcard.2018.03.113.
   PubMed Web of Science ®Google Scholar
• Bui QM, Simpson S, Nordstrom K. Psychiatric and medical management of marijuana intoxication in the emergency department. West J Emerg Med. 2015;16(3):414–417. doi:10.5811/westjem.2015.3.25284.
   PubMed Web of Science ®Google Scholar
• Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin. 2001;51(4):232–248. quiz 249-52. doi:10.3322/canjclin.51.4.232.
   PubMed Web of Science ®Google Scholar
• Van Fleet S. Relaxation and imagery for symptom management: improving patient assessment and individualizing treatment. Oncol Nurs Forum. 2000;27(3):501–510.
   PubMedGoogle Scholar
• Bayuk L. Relaxation techniques: an adjunct therapy for cancer patients. Semin Oncol Nurs. 1985;1(2):147–150. doi:10.1016/S0749-2081(85)80049-8.
   PubMedGoogle Scholar
• Ahles TA, Tope DM, Pinkson B, Walch S, Hann D, Whedon M, Dain B, Weiss JE, Mills L, Silberfarb PM. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manage. 1999;18(3):157–163. doi:10.1016/S0885-3924(99)00061-5.
   PubMed Web of Science ®Google Scholar
• Hines S, Steels E, Chang A, Gibbons K. Aromatherapy for treatment of postoperative nausea and vomiting. Cochrane Database Syst Rev. 2018; 3(3):CD007598. doi:10.1002/14651858.CD007598.pub3.
   PubMedGoogle Scholar
• Wu X, Chung VC, Hui EP, Ziea ET, Ng BF, Ho RS, Tsoi KK, Wong SY, Wu JC. Effectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews. Sci Rep. 2015;5:16776. doi:10.1038/srep16776.
   PubMed Web of Science ®Google Scholar